INTRODUCTION
Granulocyte-macrophage colony-stimulating factor (GM-CSF, Csf-2) plays an important role in tissue-targeted autoimmune diseases (Becher et al., 2017; Hamilton, 2015) . In the pathogenesis of rheumatoid arthritis (RA), the involvement of GM-CSF has been indicated by its presence in the synovial fluid of RA patients (Xu et al., 1989) and the attenuation of collageninduced arthritis in GM-CSF-deficient mice (Campbell et al., 1998) . Moreover, clinical trials testing GM-CSF-neutralizing antibodies in patients with RA show disease amelioration (Burmester et al., 2013) . In colitis, opposing outcomes have been reported depending on the model used: GM-CSF-deficient mice are slightly more susceptible to dextran sulfate sodium (DSS)-induced colitis (Xu et al., 2008) , whereas anti-GM-CSF treatment attenuates interleukin (IL)-23-driven T cell transfer colitis as well as Helicobacter-induced colitis (Griseri et al., 2015 (Griseri et al., , 2012 .
In experimental autoimmune encephalomyelitis (EAE), which serves as a mouse model for multiple sclerosis (MS), GM-CSF is absolutely necessary for disease development (McQualter et al., 2001) . Specifically, the ability of neuro-antigen-specific Th cells to produce GM-CSF is a critical, non-redundant factor in the pathogenesis of EAE (Codarri et al., 2011; El-Behi et al., 2011) . In MS, GM-CSF is elevated in the cerebrospinal fluid (CSF) of patients (Carrieri et al., 1998) and increased frequencies of GM-CSF-producing memory Th cells have been reported in MS patients (Hartmann et al., 2014; Noster et al., 2014) . Furthermore, GM-CSF-driven expansion of myeloid cells has been described to induce histiocytosis-like lesions (van Nieuwenhuijze et al., 2014) implying a role for GM-CSF in histiocytic disorders such as Erdheim-Chester disease (ECD), a form of non-Langerhans-cell histiocytosis (non-LCH) (Wilejto and Abla, 2012) . In ECD the clinical phenotype can range from asymptomatic bone lesions to multi-organ variants affecting the bone, kidneys, lungs, skin, and central nervous system (CNS) (Wilejto and Abla, 2012) .
While GM-CSF is clearly necessary for the development of immunopathology in inflammation, the pathophysiological consequences of dysregulated GM-CSF expression alone are unclear. To address this question, we generated a transgenic mouse line allowing the induced expression of GM-CSF in peripheral CD4 + T cells. Surprisingly, dysregulation of GM-CSF alone was sufficient to induce severe and clinically manifest neuro-inflammation. Inflammatory foci in the CNS were dominated by tissue-invading phagocytes located mainly in meninges and the brain parenchyma, infiltrating into the brain stem. These CNS-infiltrating myeloid cells produced inflammatory mediators including reactive oxygen species (ROS Figure 1A ). GM-CSF was elevated in the serum ( Figure 1B ) and co-expressed in a large fraction of stimulated EGFP + splenic Th cells ( Figure 1C ). Analysis of splenocytes without further in vitro activation showed that 50% of EGFP + Th cells co-expressed GM-CSF ( Figure S1C ). Figures 1D and 1E ). Those resembled inflammatory monocyte-derived myeloid cells, which have been termed monocyte-derived dendritic cells (moDCs) or inflammatory macrophages: a cell type originating from monocytes under inflammatory conditions. Recently, attempts have been made toward a unified nomenclature for myeloid cells and it was suggested to call these cells monocyte-derived cells (Guilliams et al., 2014) . To investigate at which stage and to what extent dysregulated GM-CSF affects myeloid cell development, we analyzed hematopoietic cells within the bone marrow (BM). Inflammatory monocytes, neutrophils, and macrophages were increased in Csf2 CD4 mice ( Figure S1D ). Flow cytometric analysis of precursor cells (Hettinger et al., 2013) showed reduced frequencies of monocyte-macrophage DC progenitors (MDPs) and common monocyte progenitors (cMoPs) (Figures S1E and S1F), suggesting that an enhanced egress of cells from the BM contributes to the expansion of inflammatory monocyte-derived cells.
The frequency of CD4 + T cells in the blood and lymphoid organs was slightly decreased whereas the absolute number was not altered (data not shown). A more detailed analysis of the activation status, chemokine receptor, and cytokine profile of T cells in Csf2 CD4 mice ( Figure 1F ) showed an activated phenotype and increased frequencies of CCR4 + , CCR6 + , and CCR9 + T cells, while CCR7 was reduced ( Figure 1G ). The cytokine profile was largely unaltered (IL-17A, IFN-g, and RORgt), with only tumor necrosis factor (TNF)-a production being reduced in Csf2 D4 mice ( Figure 1H ). Of note, the profile of GFP + and GFP À T cells was similar (data not shown), indicating that GM-CSF expression per se does not affect T cells directly. Thus, we conclude that increased GM-CSF production by T cells leads to the expansion of myeloid cells, most prominently inflammatory monocyte-derived cells.
Dysregulated GM-CSF Induces Neurological Deficits Accompanied by Infiltration of Phagocytes into the CNS Next we analyzed the extent to which GM-CSF-driven myelopoiesis would result in pathology and clinical manifestations. We observed that tamoxifen-treated Csf2 CD4 mice invariably developed severe neurological deficits after 12 ± 4 weeks ( Figures  2A and 2B ). These animals presented with a profound lack of balance, circling around a vertical axis and then progressing into rolling along their body axis (for the detailed scoring system, see the Supplemental Experimental Procedures). Occasionally, mice exhibited tail and limb paralysis. The clinical incidence reached 97% (52/53 mice) compared to 0% in control littermates (Figures 2A and 2B ). The mean maximum score of diseased mice reached 3.1 ± 1 ( Figure 2C ). This showed that dysregulated expression of GM-CSF in polyclonal Th cells alone could induce neurological deficits.
To directly compare the effects of GM-CSF overproduction with those of IL-17A, another cytokine implicated in CNS inflammation, we made use of IL-17A inducible mice (Il17a IND/WT ) (Haak et al., 2009 ) and also crossed them to the Cd4-creERT2 strain (henceforth Il17a   CD4 ). The mice showed virtually identical recombination efficiency ( Figure S2A ) and equal frequencies of IL-17A-and GM-CSF-expressing cells (data not shown). However, 
Il17a
CD4 mice did not exhibit expansion of myeloid cells in the blood ( Figure S2B ) and did not develop neurological deficits (Figures 2D-2F) .
We next altered the frequencies of GM-CSF-producing T cells to determine the threshold required for the development of neurological deficits. First, we shortened the application of tamoxifen-laden chow from 30 to 10 days, resulting in a reduction of the recombination frequency in Th cells from 70% to 35% and consequently diminished expansion of inflammatory myeloid cells (Figures S2C and S2D) . Although with delayed onset, these mice still developed neurological deficits with similar incidence (90%) and severity ( Figures S2E-S2G ). Second, we generated mixed BM chimeras and titrated the frequencies of transgenic BM cells. This resulted in a dosedependent titration of EGFP + CD4 + T cells and responding monocyte-derived cells ( Figure S2H ) as well as neurological deficits starting at 10% of Csf2 CD4 BM ( Figure S2I ). High frequencies of GM-CSF-producing T cells led to lethality ( Figure S2I ), probably because of multiple factors including tissue damage by irradiation and a cytokine storm with high amounts of GM-CSF in the system. The clinical phenotype of Csf2 CD4 mice was predominantly neurological, so we analyzed the CNS tissue for changes in immune cell composition. Prior to clinical disease onset, we detected no influx of CD4 + and CD8 + T cells. In contrast, the frequency of CNS-infiltrating myeloid cells, both neutrophils and inflammatory myeloid cells, increased compared to control animals (Figures S3A and S3B) . After onset of neurological deficits, infiltrating myeloid and T cells were increased, with the most abundant cell type being monocyte-derived cells (Figures 2G and 2H) .
To investigate the impact of elevated GM-CSF on the CNSresident macrophages, we analyzed microglia cells by flow cytometry before Csf2 CD4 mice developed neurological deficits. We did not find alterations in the total counts or in the expression of classical activation markers of microglia ( Figures 2I-2K ). Cell sorting and gene expression analysis revealed unchanged expression of Sall1, Tgfbr2, Mip1a, and Mip1b. However, Mcp1 (Ccl2) , Tnfa, and Il1b expression was slightly increased in microglia from Csf2 CD4 mice (Figures 2I and 2L) . Even though microglia were largely unaffected in Csf2 CD4 mice before disease onset, microglia became clearly reactive upon disease onset and progression. Iba-1 staining revealed that the ramified morphology of microglia changed toward shorter processes in clinically affected mice ( Figure 2M ). In diseased Csf2 CD4 mice, a large number of PAS + leukocytes invaded the CNS and accumulated in the meninges, scattering into the brain parenchyma ( Figures 3A and 3B ). In addition, those cells penetrated from perivascular inflammatory foci into the CNS and often formed solid masses in particular in the brain stem regions ( Figure 3A ). 3D ). Of note, it has been suggested that monocyte-derived cells could induce demyelination (Yamasaki et al., 2014) . Taken together, we observed a specific pattern of inflammatory myeloid cell infiltrates in different CNS compartments upon dysregulated GM-CSF expression and a corresponding neurological phenotype.
Dysregulated GM-CSF Leads to CNS Inflammation Independent of T Cell Receptor Specificity
IL-23 has been shown to critically shape the encephalitogenic profile in Th cells and to stabilize GM-CSF polarization (Codarri et al., 2011; Croxford et al., 2012; Sonderegger et al., 2008) .
To investigate the contribution of IL-23 to GM-CSF-driven inflammation, we crossed Csf2 CD4 mice to an IL-23p19-deficient background (Csf2 CD4 Il23a À/À ). We found that after GM-CSF induction, Il23a-deficient mice showed a similar incidence, onset, and CNS disease severity compared to Il23a-sufficient mice ( Figures 4A-4C ), demonstrating that IL-23 is dispensable for the formation of inflammatory CNS lesions in this model. To determine whether increased frequencies of CNS-antigenreactive T cells would exacerbate the kinetics and/or severity of CNS disease in our model, we crossed the Csf2 CD4 mice to 2D2 T cell transgenic mice (Csf2 CD4 2D2), harboring a T cell receptor (TCR) specific for the myelin component myelin oligodendrocyte glycoprotein (MOG) (Bettelli et al., 2003) . Tamoxifen-treated ; PAS, periodic acid-Schiff. Please see also Figure S3 .
GM-CSF-Induced Myeloid Cells Infiltrate Different Organs but Caused Immunopathology in the CNS
We further assessed Csf2 CD4 mice for signs of tissue damage across different organs and screened various organs for inflammatory infiltrates and signs of tissue destruction at a late time point (>10 weeks after tamoxifen treatment start, after onset of neurological deficits), which allows sufficient time for the manifestation of organ damage. Early on (week 6 after tamoxifen treatment start), we observed opacity of the eyes in Csf2 CD4 mice (data not shown). Histological analysis showed immune cell infiltrates in the retina, with destruction of the retinal layers and pigment epithelium ( Figures 5A and 5B ). Even though in liver, lung, and kidney immune infiltrates were present, no obvious histostructural changes were found ( Figures 5A and 5B ). We did not detect inflammatory infiltrates in skin and pancreas and the overall organ structure remained intact ( Figures 5A and 5B) . In the colon, we could not detect inflammatory infiltrates or structural alterations between Csf2 CD4 and control mice ( Figures 5A and 5B). Further, Csf2 CD4 mice did not present with clinical signs of colitis such as diarrhea. The intestinal wall of the colon remained translucent (data not shown) and the colon length was unaltered ( Figure 5C ). Also, joints and paws did not show any overt signs of inflammation ( Figures 5A and 5B and data not shown). Next, we quantified the leukocyte content of liver, lung, and kidney. Overall, myeloid cells were severely affected by elevated GM-CSF in Csf2 CD4 mice, whereas T cells were hardly increased ( Figure 5D ). To compare inflammatory monocyte-derived cells and neutrophils in several organs, we calculated the ratio of im- myeloid cells to be highest in the CNS (125-fold), followed by liver and lung. In contrast, the increase of neutrophils was highest in the liver followed by lymph node (LN) and spleen and was relatively low in the CNS ( Figure 5E ). This suggests that GM-CSF-induced myeloid infiltrates considerably varied in absolute number and composition between organs. Furthermore, we used dimensionality reduction to study the myeloid compartment in an unbiased fashion Mair et al., 2016) . The most striking differences were the emergence of inflammatory myeloid cells in the CNS as well as the lung (Figures S4A-S4C) .
In order to assess whether the vulnerability to tissue damage correlates with the time point of infiltration, we analyzed organs as early as 9 days after a short pulse of tamoxifen. CD45 + cells and inflammatory monocyte-derived cells were increased in Csf2 CD4 over control mice in the LN, lung, and the liver. In contrast, blood, spleen, and CNS were hardly affected at this time point ( Figure S5A ). Overall, these data show that liver and lung tissue invasion clearly preceded the CNS and that there is no correlation between the time point of immune cell infiltration and immunopathology.
To screen for subclinical signs of organ dysfunction, we analyzed serum samples for parameters indicating dysfunction of liver (aspartate aminotransferase, alanine aminotransferase, bilirubin, and cholinesterase), pancreas (amylase, glucose), kidney (urea), and muscle (creatine kinase) but failed to detect changes in all but two of those markers in Csf2 CD4 mice compared to control littermates ( Figures S5B and S5C ). The concentration of serum urea was slightly elevated in diseased Csf2 CD4 mice; therefore, we cannot exclude mild renal dysfunction ( Figure S5C) . Also, one of four liver parameters (cholinesterase) showed a small reduction in diseased Csf2 CD4 mice ( Figure S5C ). To assess lung function, we performed blood gas analysis from mice before and after onset of neurological deficits but found no alteration in the partial pressure of CO 2 or O 2 ( Figure S5B, S5D, and S5E ). Likely as a result of the extensive myeloid cell expansion, a reduction of total hemoglobin was found in diseased Csf2 CD4 mice. However, the proportion of oxygenated hemoglobin was not altered ( Figure S5E ). In summary, these data suggest that, in contrast to the other tissues, the CNS is particularly vulnerable to infiltration and damage mediated by GM-CSF-expanded myeloid cells.
GM-CSF-Expanded Infiltrating Myeloid Cells Can Cause Localized CNS Tissue Injury
Based on the distribution of myeloid cell infiltrates in the CNS and the proximity of inflammatory myeloid cells to CNS nerve and glia structures, we next investigated the CNS tissue integrity. CD11c + myeloid cells accumulated in subpial regions in the CNS of Csf2 CD4 mice, penetrating into the parenchyma and occasionally forming mass-like conglomerates ( Figure S6A ). Additionally, infiltrating CD11c + myeloid cells clustered around blood vessels ( Figure S6A ). In the brain, CD11c + myeloid cell infiltrates co-localized with areas of reduced CNPase (2 0 ,3 0 -Cyclic-nucleotide 3 0 -phosphodiesterase) immunoreactivity indicating myelin breakdown at sites with numerous myeloid cells ( Figure S6A) Figure 6A ) and occasionally proteolipid protein (PLP) + debris ( Figure S6B ), demonstrating ongoing myelin destruction and phagocytosis ( Figure 6B ). These findings were further corroborated by a substantial loss of myelin and nerve fibers, indicated by the reduction of PLP and neurofilament signal in the brain stem of diseased Csf2 CD4 mice ( Figures 6C-6E ).
We observed reactive astrogliosis in the tissue adjacent to infiltrates (indicated by increased GFAP signal intensity; Figures  S6C and S6D ), whereas when more solid myeloid cell masses were formed, astrocytes were largely lost ( Figure S6C ). We conclude that GM-CSF-driven expansion of myeloid cells leads to myeloid cell infiltrates replacing and/or destroying CNS tissue at site.
CNS-Infiltrating Myeloid Cells Produce Elevated Amounts of Reactive Oxygen Species
To determine how GM-CSF elicits CNS tissue destruction in our model, we assayed potential effector functions of CNS-infiltrating inflammatory myeloid cells. It was reported previously that inflammatory cytokines such as IL-1b are involved in neuro-inflammation (Argaw et al., 2006) and non-LCH (Aouba et al., 2010) . Prior to onset of neurological deficits, splenic inflammatory myeloid cells of Csf2 CD4 mice showed increased IL-1b or proIL-1b production ( Figures 6F and 6G) . In CNS homogenates, IL-1b, IL-6, and TNF-a were increased in Csf2 CD4 compared to control mice ( Figure 6H ). One tangible mechanism as to how inflammatory monocytederived cells could directly lead to neuronal dysfunction is by the production of ROS, which have been implicated in MS lesion formation (Haider et al., 2011; Vladimirova et al., 1999) . Accordingly, we found p22phox + (cyba, a subunit of the NADPH oxidase) cells in the brain stem of diseased Csf2 CD4 mice ( Figure 6I ). When we compared ROS expression in several organs of Csf2 CD4 mice, it was highly elevated in inflammatory phagocytes compared to Csf2 IND controls ( Figures 6J and 6K) . Furthermore, ROS production in Csf2 CD4 mice was highest in the CNS compared to spleen, liver, and lung ( Figure 6L ). In addition, the variability in ROS production by myeloid cells between different organs suggests that either intrinsically or by the influence of the particular tissue microenvironment, myeloid cells differ in their response profile.
The CNS Microenvironment Shapes the Signature of Infiltrating Myeloid Cells
In order to determine the impact of the tissue microenvironment on invading myeloid cells, we chose two different approaches. First we compared the tissue stroma response to myeloid invasion between the CNS and the lung. We isolated RNA from CD45 À cells obtained from CNS and the lung of Csf2 CD4 and control mice at different time points ( Figure S7A ) and performed RNA sequencing. Comparison of gene expression in the CNS stroma of Csf2 CD4 mice after the development of neurological deficits (called CNS after) to Csf2 IND control mice (called CNS control) revealed >100 genes differentially expressed. In stark contrast, in the lung stroma only 10 genes were differentially regulated ( Figure S7B ). We used the differentially expressed genes from the CNS (CNS after versus CNS control) to cluster all the samples and found only minor differences in the CNS of Csf2 CD4 mice before and after the development of neurological (Csf2   IND   ) mice; n = eye 7 (7), liver 10 (7), lung 10 (5), kidney 6 (6), ear 6 (3), pancreas 8 (8), colon 10 (7), and joints 8 (8).
(C) Colon length in Csf2 CD4 mice and controls, pooled data from 3 independent experiments with n = 3-5/group.
(D) Total counts of infiltrates in liver, lung, and kidney; pooled data from 3 (liver), 5 (lung), or 4 (kidney) independent experiments with n = 3/group, gating as in Figure 1F . deficits ( Figure S7C ). This is in line with flow cytometric data (Figures S3A and S3B), which shows that infiltrating cells are already found at this time point, suggesting an early response of the tissue microenvironment upon entry of myeloid cells. Second, we performed RNA sequencing of flow cytometrypurified inflammatory myeloid cells obtained from the CNS, spleen, lung, liver, and kidney of Csf2 CD4 mice ( Figure S7D ).
Strikingly, multidimensional scaling of individual samples based on their global gene expression profiles revealed that the inflammatory myeloid cells from the CNS clustered together but very distinct from cells isolated from the spleen, lung, liver, and kidney ( Figure 7A ). Myeloid cells in the CNS had a vastly different gene expression profile compared to inflammatory myeloid cells from all other organs ( Figure 7B ), with $2,000 genes significantly changed ( Figure 7C ). The most drastically altered pathways involved the immune response, cell proliferation, membrane organization, and endocytosis ( Figure S7E ). Gene ontology analysis revealed that in CNS-invading myeloid cells, transcripts for antigen processing and presentation were downregulated whereas genes related to lipid metabolic processes showed a general enrichment ( Figures 7D and  7E ). Transcripts involved in chemokine-mediated signaling pathways (including Trem2) and phagocytosis marker such as CD64 (Fcgr1) and Mertk were found among differentially expressed genes ( Figure 7F ). Corroborating our findings that CNS-infiltrating myeloid cells can take up myelin debris and produce ROS, several genes relevant for phagocytosis and ROS generation were changed in the CNS (Figures 7G  and 7H ). Among the downregulated genes was superoxid dismutase 1 (Sod1), an enzyme necessary for neutralizing superoxide radicals, while the cytochrome b beta chain (Cybb), participating in a chemical reaction that can convert oxygen to superoxide, was upregulated. Overall, CNS-invading inflammatory myeloid cells exhibited a highly altered gene expression profile compared to the same subset of myeloid cells, which had invaded lung, liver, and kidney, suggesting that the CNS tissue environment particularly influences their effector function.
DISCUSSION
The importance of GM-CSF for the expansion of myeloid cells was reported previously using global GM-CSF overexpression models, where constitutive GM-CSF expression resulted in premature death (Johnson et al., 1989; Lang et al., 1987; van Nieuwenhuijze et al., 2014) . In contrast, controlled, induced expression of GM-CSF in the endogenous polyclonal Th cell pool caused the expansion of inflammatory phagocyes, accompanied by spontaneous CNS inflammation and severe neurological impairment. This phenotype was robust over a wide range of frequencies of GM-CSF-producing T cells, suggesting that dysregulated GM-CSF alone is sufficient to provide inflammatory myeloid cells with the capacity to invade the CNS and cause tissue inflammation.
Overexpression of IL-17A in a manner equal to that of GM-CSF by T cells did not induce neurological deficits, showing that the phenotype we observed with Csf2 CD4 mice is not a result of overexpression of pro-inflammatory cytokines per se. The global inducible expression of IL-17A mainly affected epithelial tissues like the skin, while no CNS inflammation was reported (Haak et al., 2009 ). GM-CSF production by Th17 cells can be induced by IL-1 (Croxford et al., 2015a; El-Behi et al., 2011) . In vivo, pertussis toxin, a reagent commonly used to facilitate EAE development, has been shown to induce IL-1 production by CCR2 + myeloid cells in the LN (Lin et al., 2016; Ronchi et al., 2016) . Of note, IL-1 signaling is required for the encephalitogenic potential of T cells via induction of the transcription factor bhlhe40 and the co-production of GM-CSF and IFN-g in T cells (Lin et al., 2016; Ronchi et al., 2016) . Thus, the dysregulated GM-CSF expression in Csf2 CD4 mice appears to overcome the requirement for T cells to sense IL-1 and IL-23 to elicit their pathogenic potential. Even though we used Th cells to deliver higher amounts of GM-CSF, we found that TCR specificities or cytokine signaling in Th cells had no bearing on disease development. Of course, during EAE and MS, T cells are the most potent source of GM-CSF and thus required for disease progression, but when we bypassed encephalitogenic T cells by dysregulating GM-CSF in polyclonal Th cells or myeloid cells (Cd4-creERT2 or Ccr2-creERT2), we found that once GM-CSF had reached a certain threshold, the subsequent activation of phagocytes was sufficient to mediate CNS pathology. In fact, in most T-cell-driven inflammatory diseases it is unlikely that Th cells damage tissue directly. Instead, phagocytes are better equipped to be mediators of tissue destruction (Croxford et al., 2015b) . We found that GM-CSF-expanded inflammatory myeloid cells produced inflammatory mediators, such as IL-1b and ROS.
GM-CSF-induced infiltration of inflammatory phagocytes was mainly found in the CNS, liver, and lung whereas organs such as skin, colon, and pancreas were spared, suggesting that the specific tissue microenvironments harbor different cues for the invasion of myeloid cells. Most prominently, dysregulation of GM-CSF resulted in clinically overt neurological deficits and eye opacity whereas evident liver and lung damage was not observed. Based on serum parameters, mild liver and renal dysfunction cannot be completely excluded, whereas blood gas analysis did not reveal impairment of lung function. Together with the fact that liver and lung were invaded by myeloid cells even before the CNS, it is unlikely that pathologies in other organs relative to the CNS would have occurred at a later point.
The notion that the CNS is particularly vulnerable to the invasion of myeloid cells is supported by the fact that the CNS stroma responded strongly to the tissue invasion, whereas the lung stroma showed hardly any reaction. Conversely, CNS-invading inflammatory phagocytes acquired a unique genetic signature compared to inflammatory phagocytes in all other organs analyzed (lung, liver, kidney), suggesting that the microenvironment of the target tissue itself influences the effector function of these cells. This opens up a possible venue to specifically target myeloid cells in the CNS. The potential and current pitfalls of using CNS myeloid cells as drug targets were reviewed recently (Biber et al., 2016) . Most intriguing is as to why the CNS is more affected by infiltrating inflammatory myeloid cells. We noted a downregulation of CCR2 on inflammatory phagocytes in the CNS compared to other organs. As this was reported to be a feature of the transition of monocytes to macrophages in vitro, it could suggest that CNS myeloid cells exhibit a more differentiated phenotype (Fantuzzi et al., 1999) , in line with upregulation of Mertk and CD64. We also found upregulation of Trem-2 and Cybb, molecules expressed by macrophages in demyelinating lesions in MS (Fischer et al., 2012; Piccio et al., 2008) .
On the other hand, the topographic architecture of the target organ itself could favor tissue damage, as the regenerative capacity of the CNS is very limited, making it less likely that damage caused by an invading phagocytic cell can be repaired to an extent that the functionality is restored. Another specific feature of the CNS is the high content of lipids, resulting from the composition of the myelin sheet. One can speculate that the extensive upregulation of genes involved in the lipid metabolism is correlated to the lipid content in the CNS.
The CNS inflammatory disease induced by dysregulated GM-CSF does resemble features of the immunopathology seen in MS and other human disease entities such as non-LCH. For both, dysregulated GM-CSF has been associated with disease activity and/or development (Al-Homaidhi et al., 1998; Carrieri et al., 1998) . Sites of predilection of MS lesions include the brain stem (Kuhlmann et al., 2008) , correlating with the location of infiltrates in our model. Conversely, the spectrum of non-LCH is characterized by expansion of cells from the monocyte-macrophage lineage and various CNS pathologies (Cives et al., 2015) . Using a non-inducible transgenic model, it has been indicated previously that GM-CSF-driven expansion of myeloid cells could mimic aspects of histiocytosis in lung and bone marrow (van Nieuwenhuijze et al., 2014) . The clinical prognosis for patients with ECD suffering from CNS inflammation is particularly poor and efficient treatment regiments are yet to be defined (Cives et al., 2015; Wilejto and Abla, 2012) . Our study provides a rationale that blocking GM-CSF could be considered for clinical testing in histiocytic disorders.
Overall, our findings emphasize the pathogenic, tissuedestructive role of GM-CSF-polarized myeloid cells in inflammation, to which the CNS was particularly vulnerable. We propose that dysregulated GM-CSF expression, as observed in chronic inflammatory diseases, can direct myeloid cell infiltration and accumulation into target tissues. These data also steer away from T cells as culprits in mediating tissue destruction toward a myeloid cell with the ability to invade the tissue and to cause damage locally. Future work will reveal the tissue-specific cues guiding the effector functions of myeloid cells.
EXPERIMENTAL PROCEDURES

Generation of Csf2
IND Mice
The targeting strategy is depicted in Figure S1A . For homologous recombination in the Rosa26 locus, ZFN were used as described in the Supplemental Experimental Procedures. Two mice carrying the targeting construct were obtained and confirmed by Southern blot ( Figure S1B ).
Mice and In Vivo Manipulations
Mice were kept in individually ventilated cages under specific-pathogen-free conditions. C57BL/6 (wild-type) mice were purchased from Janvier Laboratories, Il23a À/À from Regeneron, and OT-II from Jackson. 2D2 mice were provided by V. Kuchroo (Harvard Medical School, Boston). Cd4-creERT2 mice were described (Sledzi nska et al., 2013 ). Il17a IND were described (Haak et al., 2009 ). All animal experiments were approved by local authorities (Swiss cantonal veterinary office). Tamoxifen treatment is described in detail in the Supplemental Experimental Procedures. For clinical scoring, mice with rotatory neurological deficits were evaluated on a scale from 0-5 (Greer et al., 1996) : 0, no detectable signs; 1, head turned slightly; 2, head turning more pronounced; 3, cannot walk in a straight line; 3.5, walks in circles; 4, cannot stand but lie on their side; 5, rolls continuously. For spinning when held by the tail, 0.5 was added to each score.
Flow Cytometry
Antibody clones are listed in the Supplemental Experimental Procedures. For staining of ROS, CellROX Deep Red reagent (Life Technologies) was used. For intracellular cytokine staining, T cells were incubated 4 hr at 37 C in RPMI containing 10% FCS with PMA (50 ng/mL), ionomycin (500 ng/mL), and Brefeldin A (BD); myeloid cells with Brefeldin A (BD). Flow cytometric analysis was carried out using a FACSCanto II (BD) or a LSR II Fortessa (special order research product, BD) with FACS Diva Software. Cell sorting is described in detail in the Supplemental Experimental Procedures.
RNA Isolation and Quantitative RT-PCR
Total RNA was isolated from sorted microglia using the RNeasy Plus Micro kit (QIAGEN) and cDNA was generated using SuperScript II (Invitrogen) according to manufacturer's instructions. Gene expression was measured by qPCR analysis using the CFX 384 system (Bio-Rad) with SYBR Green Supermix (Bio-Rad). Primer sequences can be found in the Supplemental Experimental Procedures. Transcript expression was normalized to Polr2a.
Blood Gas Analysis
Venous blood was analyzed on a ABL80 FLEX CO-OX, provided by the Zurich Integrative Rodent Physiology platform at the University of Zurich.
Histology and Immunohistochemistry
For histo-pathological assessment, organs were fixed in HOPE, joints in 4% PFA, and stained with hematoxylin and eosin. Intensity of immune cell infiltration was quantified by scoring tissue sections: >4 (most severe), 2-3 (severe), 1-2 (mild), and 0 (none). LFB-PAS stainings were done according to standard protocols on 4% PFA-fixed, paraffin-embedded 6 mm tissue sections. For immunohistochemical stainings see Supplemental Experimental Procedures.
Immunofluorescent Tissue Stainings CNS tissue was fixed with 4% PFA, followed by cryoprotection with 30% sucrose in PBS. 20-to 40-mm-thick free-floating sections or 12-mm-thick sections were cut in a cryostat. The CD11c and CNPase stainings were performed on 12 mm cryopreserved sections that were fixed using PFA and acetone. Antibodies are listed in the Supplemental Experimental Procedures. Fluorescence photomicrographs were taken with a SP5 Leica confocal laser scanning microscope (SP5; Leica).
Next Generation Sequencing
Total RNA was isolated from flow cytometry-sorted CD45
À cells or inflammatory monocyte-derived cells using the RNeasy Plus Micro kit (QIAGEN) according to manufacturer's instructions. NGS was performed by the Functional Genomics Center Zurich (FGCZ) using the HiSeq 4000 System (Illumina) or the Genomics Facility Basel using the HiSeq 2500 System (Illumina). Bioinformatic analysis was performed using SUSHI, differential expression analysis was performed using edgeR.
Statistical Analysis
Data are displayed as individual data points with mean ± standard deviation (SD) for scatterplots and as mean ± standard error of the mean (SEM) for bar graphs.
ACCESSION NUMBERS
Sequencing data are available in the ArrayExpress database (http://www.ebi. ac.uk/arrayexpress) under accession numbers E-MTAB-5412 (for myeloid cells) and E-MTAB-5414 (for CD45 À cells).
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